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Background: DNA methylation can be abnormally regulated in human disease and associated with effects on gene
transcription that appear to be causally related to pathogenesis. The potential to use pharmacological agents that reverse
this dysregulation is therefore an attractive possibility. To test how 5-aza-2′-deoxycytidine (5-aza-CdR) influences the
genome therapeutically, we exposed non-malignant cells in culture to the agent and used genome-wide assays to assess
the cellular response.
Results: We found that cells allowed to recover from 5-aza-CdR treatment only partially recover DNA methylation levels,
retaining an epigenetic ‘imprint’ of drug exposure. We show very limited transcriptional responses to demethylation of
not only protein-coding genes but also loci-encoding non-coding RNAs, with a limited proportion of the induced genes
acquiring new promoter activation within gene bodies. The data revealed an uncoupling of DNA methylation effects at
promoters, with demethylation mostly unaccompanied by transcriptional changes. The limited panel of genes induced by
5-aza-CdR resembles those activated in other human cell types exposed to the drug and represents loci targeted for
Polycomb-mediated silencing in stem cells, suggesting a model for the therapeutic effects of the drug.
Conclusions: Our results do not support the hypothesis of DNA methylation having a predominant role to regulate
transcriptional noise in the genome and indicate that DNA methylation acts only as part of a larger complex system of
transcriptional regulation. The targeting of 5-aza-CdR effects with its clastogenic consequences to euchromatin raises
concerns that the use of 5-aza-CdR has innate tumorigenic consequences, requiring its cautious use in diseases involving
epigenetic dysregulation.Background
With the increasing recognition that disturbances in DNA
methylation (5-methylcytosine (5mC)) occur in a variety
of human diseases, attention is focusing on how these in-
sights could translate into therapeutic approaches. The
field of epigenetic therapeutics has its foundations in can-
cer biology [1], but the recognition that epigenetic regula-
tory mechanisms appear to be contributing to diseases
other than cancer has prompted discussion of the use of
these agents in a broader spectrum of diseases [2]. Targets
for epigenetic therapies include DNA methylation and
post-translational modifications of histones, including
acetylation and methylation, by targeting the enzymes that
add these covalent marks. As DNA methylation is* Correspondence: john.greally@einstein.yu.edu
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unless otherwise stated.currently the best studied of all candidate epigenetic regu-
lators in human diseases, much attention has focused on
DNA methyltransferase (DNMT) inhibitors. Several
agents have been described to act as DNMT inhibitors:
the nucleoside inhibitors 5-azacytidine (5-aza-CR), 5-aza-
2′-deoxycytidine (5-aza-CdR), and zebularine; the non-
nucleoside inhibitors procaine, epigallocatechin-3-gallate
(EGCG), and hydralazine; and the direct DNMT inhibitor
RG108 [3,4]. Of these, 5-aza-CdR (decitabine) has been
found to be the most effective at demethylating DNA [3]
and is approved for the treatment of myelodysplastic syn-
drome (MDS) in human subjects.
Incorporation of 5-aza-CdR into the genome causes it
to be recognized by mammalian DNMT1 which be-
comes irreversibly bound to the nucleoside, unable to
perform its catalytic functions, and leads it to become
prematurely degraded, potentially involving ubiquitin-This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion of the genome, especially in promoter regions, is a
goal of oncological therapy, prompted by observations of
the acquisition of DNA methylation at transcription start
sites and the associated transcriptional silencing of
tumor-suppressor genes [6]. Resistance to 5-aza-CdR
has been found to involve differences in rates of incorp-
oration of the nucleoside into DNA [7]. We have previ-
ously found that CD34+ hematopoietic stem and
progenitor cells (HSPCs) from patients with MDS have
distinctive DNA methylation patterns when compared
with CD34+ HSPCs from control subjects and that treat-
ment with 5-aza-CR induces loss of DNA methylation at
promoters in these cells [8]. In cell models of leukemia,
genomic studies have indicated that 5-aza-CR and 5-aza-
CdR both induce demethylation of CG dinucleotide-rich
CpG islands at promoters, but these promoter changes
are not associated with transcriptional effects at those
genes [9]. We have also previously observed that long-
term hematopoietic stem cells (HSCs, lineage−/CD34+/
CD38-/CD90+) in MDS have abnormal DNA methyla-
tion compared with the same cell type from healthy con-
trol subjects and that treatment with 5-aza-CR does not
influence the levels of mosaicism for cytogenetic abnor-
malities in these HSCs, indicating that the therapeutic
response is through effects on the functional properties
of these neoplastic cells rather than their eradication
[10]. A major concern with the use of DNMT inhibitors
is their potential to induce genomic rearrangements,
traditionally attributed to global demethylation based on
cytogenetic observations made in the immunodeficiency,
centromeric region instability, facial anomalies (ICF)
syndrome [11] but also attributable to the formation of
DNMT1 adducts in cells treated by 5-aza-CdR [12].
The genomic response to DNMT inhibitors is one of glo-
bal demethylation, but there is some heterogeneity of re-
sponse of loci within the genome. Among the regions
undergoing demethylation, some lose while others retain
nucleosomal occupancy [13], indicating that transcriptional
regulatory processes are not primarily driven by DNA
methylation and can be decoupled. With advances in tech-
nologies that allow genome-wide studies of DNA methyla-
tion, chromatin constituents, and transcription, we now
have greater opportunity for more extensive insights into
the effects of DNMT inhibitors than prior studies, which
tended to focus on gene promoter effects. In particular, we
were interested in following up on a prior paradoxical
observation that demonstrated DNA methylation to be
enriched at DNase hypersensitive, early-replicating eu-
chromatin in non-cancer cell lines [14], suggesting
that the effects of a DNA demethylating agent would
be more likely to target this gene- and transcription-rich
genomic compartment. Another question raised was
whether global DNA demethylation is causally associatedwith the emergence of cryptic promoters. This idea was
prompted by a long-established hypothesis that DNA
methylation evolved to allow the suppression of transcrip-
tional noise as genome sizes expanded, helping to prevent
spurious polymerase-DNA interactions [15]. With these
questions in mind, we performed a study to test how 5-aza-
CdR influences DNA methylation, RNA polymerase II
localization, and gene expression in cultured human embry-
onic kidney (HEK) 293 Tcells. As our previous studies were
performed in primary cell types [8,10], our preference was
to avoid using the cell lines derived from malignant cells
that are typically used in DNMT1 inhibitor studies. How-
ever, to allow our studies to be reproduced, we chose to use
the commonly used HEK 293 T cell line which is trans-
formed but not derived from cancer cells.
Results
Imprinted global demethylation following 5-aza-CdR
treatment
To test the effect of global demethylation of the genome,
we treated the HEK 293 T cell line with a range of 5-aza-
CdR concentrations. We chose HEK 293 T cells as a non-
cancer cell type that is widely available, allowing replication
of our studies and an insight into effects of DNMT1 inhibi-
tors in cells that have not undergone malignant transform-
ation. After 72 h of constant exposure to the drug, we
measured global 5mC levels by performing the Lumino-
metric Methylation Assay (LUMA) [16]. The level of 5mC
in untreated HEK 293 T cells was approximately 68% but
decreased strongly and in a dose-dependent manner follow-
ing 72 h of treatment (Figure 1a). Focusing in the 0.25 and
1.0 μM 5-aza-CdR-treated cells, conditions that showed
striking changes in DNA methylation, we allowed the
treated cells to recover and grow in culture for a further
30 days, observing that the growth rates return to pre-
treatment levels while cellular metabolic rates recover al-
most completely during this period (Figure 1c, d). However,
further LUMA measurements of total 5mC showed that
this return to normal growth was accompanied by only a
partial reacquisition of DNA methylation (Figure 1b). This
re-setting of the epigenome represents a pharmacologically
induced ‘imprinting’ of global DNA methylation levels in
these cultured cells.
DNA demethylation by 5-aza-CdR is predominantly
targeted to euchromatin
We then asked whether the 5-aza-CdR treatment affected
some genomic contexts to a greater extent than others. We
used massively parallel sequencing of ribonucleic acid
(RNA-seq) and DNA methylation assay data from un-
treated control cells to define the euchromatic and hetero-
chromatic compartments of the HEK 293 T genome, using
an approach that we have previously published [14]. In that
prior study, we showed the most transcriptionally active loci
Figure 1 Dose-dependent and imprinted demethylating effects of 5-aza-CdR. In panel (a), we show that global DNA methylation measured
by LUMA is strongly depleted in a dose-dependent manner following 3 days of 5-aza-CdR exposure. In panel (b), we show that DNA methylation
does not return to pre-exposure levels following a month of recovery in tissue culture despite (c) a return to pre-treatment cell growth rates
(normalized to the untreated cells) and (d) a near-complete recovery of cell metabolic rate (using the WST-1 assay). 5-aza-CdR, 5-aza-2′-deoxycytidine.
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at its most enriched, regions which were early replicating
and relatively DNase hypersensitive, defining them as eu-
chromatic [14]. We reproduced the same analytical ap-
proach of our prior study which had used different cell lines
(lymphoblastoid cells and fibroblasts) and showed that,
using the same self-organizing map (SOM) approach, the
genome could be compartmentalized (Figure 2a) and that
DNA methylation is enriched at areas of the highest tran-
scriptional activity (Figure 2b). We then tested whether this
euchromatic compartment of HEK 293 T cells was related
to where we saw the greatest degree of DNA demethylation
with 5-aza-CdR treatment, confirming this expectation as
shown in Figure 2c, d. As a guide to these regions, we list
the Reference Sequence (RefSeq) genes that are in these
genomic windows with the highest quantiles of gene expres-
sion and of DNA methylation in Additional file 1: Table S1.
Limited transcriptional effects of DNA demethylation by
5-aza-CdR
Having shown demethylation due to 5-aza-CdR exposure
to be targeting the most transcriptionally rich compartment
of the genome, we wanted to test whether this targeting
was reflected by any quantitative or qualitative changes in
gene expression. We therefore performed a directional
RNA-seq protocol that is not restricted to representing
transcripts with a polyA tail (adapted from [17]) and testedthe untreated and treated cell samples to test for transcrip-
tional changes using cufflinks [18]. As all four conditions
(two doses and two time points) were generating highly
comparable outcomes of profound demethylation, we used
the four conditions as biological replicates, as recom-
mended by the Encyclopedia of DNA Elements (ENCODE)
consortium [19]. Expression changes for both protein-
coding and long non-coding RNAs were extremely limited
in terms of the proportions of genes affected (Figure 3 and
Additional file 1: Tables S1 and S2), involving no more than
approximately 1% of protein-coding genes and approxi-
mately 3% of long non-coding RNAs (lncRNAs). Focusing
on the 1.0 μM acute treatment, which had the most sub-
stantial effects in terms of the number of genes altered in
terms of expression levels, we found that of the 179 up-
regulated protein-coding genes, 104 of these were anno-
tated to have multiple RefSeq isoforms, as had 37 of the 72
down-regulated genes, leaving open the possibility that pro-
moter and/or splicing differences were associated with the
altered expression of these subgroups of genes. Of the genes
induced to change expression with acute 1.0 μM 5-aza-CdR
treatment, 19.76% (50 genes) of the differentially expressed
protein-coding genes and 17.67% (229 transcripts) of the
differentially expressed lncRNAs remain altered in tran-
scription following 30 days of recovery (Figure 3). The
genes changing expression are listed in Additional file 1:
Tables S1 and S2.
Figure 2 Demethylation of the genome by 5-aza-CdR predominantly targets euchromatin. A self-organizing map (SOM) analysis shows
clear partitioning of the human genome into distinct compartments, represented by the U matrix of panel (a). This depiction shows increased
levels of gray for nodes within the SOM where there is dissimilarity between adjacent nodes in terms of genomic characteristics, illustrating the
structure of the partitioning of the information contained within the SOM. In panel (b) we see that the left partition includes the co-localization
(yellow) of the highest quantiles of DNA methylation (green) and of gene expression (red), loci we previously showed to represent the
euchromatic compartment of the genome [14]. When we overlay the loci with the greatest changes in DNA methylation resulting from the
1.0 μM 5-aza-CdR exposure (red), we see enrichment at the euchromatic compartment represented by the loci with the highest DNA methylation
levels (panel (c), green) or gene expression levels (panel (d), green). 5-aza-CdR, 5-aza-2′-deoxycytidine.
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massive pharmacologically mediated demethylation of
the genome is consistent with previous studies [9].
Our focus turned to asking why only a subset of loci
was especially prone to demethylation-induced tran-
scriptional consequences. A function for DNA methy-
lation is proposed to be to suppress transcriptional
noise in the genome by silencing cryptic promoters
[15]. To identify promoters in HEK 293 T cells and
any cryptic promoters unmasked by the demethylationfollowing 5-aza-CdR treatment, we used chromatin
immunoprecipitation followed by massively parallel se-
quencing (ChIP-seq) for serine 5-phosphorylated RNA
polymerase II (RNAPII-Ser5 (P)), which defines pro-
moter regions [20] (Additional file 1: Tables S3 and
S4). To assess the quality of these ChIP-seq promoter
predictions, we measured their CG dinucleotide com-
position. Promoters in the human genome have been
shown to be in two categories depending on their ob-
served/expected CG dinucleotide frequencies [21].
Figure 3 Limited transcriptional consequences of 5-aza-CdR-mediated genomic demethylation. We show protein-coding (a) and long
non-coding RNA (b) genes to have very limited proportions of genes that are up-regulated (green) or down-regulated (red) in exposed or
recovered cells. The proportion of genes in each situation is indicated. The x axis in each case is control cells not exposed to 5-aza-CdR at that
time point. FPKM, fragments per kilobase per million reads; lncRNA, long non-coding RNA; 5-aza-CdR, 5-aza-2′-deoxycytidine.
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using the current RefSeq annotation, we could repro-
duce the bimodal distribution of high-CG (HCG) and
low-CG (LCG) content (Figure 4) at the 3-kb flanking
RefSeq transcription start sites. The same test of ob-
served/expected CG dinucleotide frequencies for these loci
occupied by RNAPII-Ser5 (P) in untreated HEK 293 T cells
reveals a substantial shift towards the HCG category
(Figure 4). As high-CG density is a feature long used to pre-
dict promoter locations [22], we interpret the enrichment
of HCG content at sites of RNAPII-Ser5 (P) as supportive
of the quality of the ChIP-seq predictions and indicative of
the possibility that the LCG promoters defined by RefSeq
gene annotation data are enriched for a subset of false-
positive promoter predictions.
When we studied the DNA methylation patterns at
the RNAPII-Ser5 (P)-defined promoters in untreated
HEK 293 T cells, those in the HCG category exhibited
generally uniform DNA hypomethylation, whereas the
smaller LCG subgroup included a substantial proportion
of loci where the RNA polymerase is located at methyl-
ated DNA. We defined this subset of promoters as those
with DNA methylation values less than the lower 95%
confidence interval for HELP-tagging values of the HCGFigure 4 RefSeq promoter annotations are over-represented
for those with low-CG content compared with promoters used
in vivo. We reproduced a prior approach to categorize promoters
based on observed/expected CG dinucleotide frequencies [21],
showing the bimodal distribution (gray) that allows categorization
into low-CG (LCG) and high-CG (HCG) groups. ChIP-seq to localize
RNAPII-Ser5 (P) was used to define promoters used in vivo in
unexposed, control HEK 293 T cells. The same bimodal CG
dinucleotide distribution was observed (blue) but with a substantially
lower proportion of LCG promoters, suggesting that the RefSeq
annotation may include some inaccurate promoter predictions
within this LCG subcategory. CG, cytosine-guanine dinucleotide;
RNAPII-Ser5 (P), serine 5-phosphorylated RNA polymerase II.promoters (Figure 5a) and tested the expression levels of
those genes relative to the genome as a whole. The frag-
ments per kilobase per million reads (FPKM) values for
this subgroup of genes with RNAPII-Ser5 (P) at methyl-
ated loci in untreated cells indicate that these genes are
expressed at levels at least comparable to the remainder
of the genes in the genome (Figure 5b). This is an unex-
pected association of a mark for active transcription start
sites (RNAPII-Ser5 (P)) with a modification thought to
be universally repressive at promoters (DNA methyla-
tion), with indications of active expression of the associ-
ated genes.
Having gained insights into the promoters used in the
untreated cells, we then investigated the effects of 5-aza-
CdR exposure at these loci. As we were concerned that
the RefSeq-defined LCG promoters included a substan-
tial proportion of false-positive predictions, we restricted
our RefSeq-defined promoters to the HCG category as
being more likely to be accurate. We tested the two
groups of LCG and HCG promoters defined by RNAPII-
Ser5 (P) ChIP-seq as a high-confidence reference stand-
ard. We measured the DNA methylation changes and
associated RNA-seq expression differences at these three
promoter categories. A k-means clustering approach
allowed us to look for subsets of loci with transient or
‘imprinted’ changes in promoter methylation, looking for
seven clusters, one in which no changes occur, and three
each for gain and loss of DNA methylation, reasoning
that this would allow us to discriminate between early,
late, and transient changes between the acute and recov-
ery stages. This analysis revealed a minority of pro-
moters with these types of DNA methylation changes at
the three categories of promoters (Figure 6), with most
effects noted at the RNAPII-Ser5 (P) LCG category and
minimal effects at both HCG promoter groups. When
we selected those promoters with the greatest losses of
DNA methylation in each category and studied the asso-
ciated gene expression changes, we found negligible pro-
portions of genes to be manifesting a transcriptional
response (Figure 6). We conclude that even with careful
promoter annotation, categorization into HCG and LCG
subtypes, and detection of DNA methylation changes at
a substantial proportion of ChIP-seq-defined RNAPII-
Ser5 (P) promoters, transcriptional consequences of pro-
moter demethylation are very rare events.
Effects of DNA demethylation within bodies of genes
As global demethylation targeting euchromatin might be
expected to have consequences in terms of unmasking of
alternative intragenic promoters [23], we explored whether
treated cells had evidence of such events, manifesting by
the emergence of new RNAPII-Ser5 (P) ChIP-seq peaks.
We found the peaks for RNAPII-Ser5 (P) to be almost com-
pletely concordant between control and 1.0 μM 5-aza-CdR-
Figure 5 RNA polymerase II is located at a subset of transcriptionally active, methylated LCG promoters. When we study the LCG and
HCG promoters defined by RNAPII-Ser5 (P) from Figure 4, we find that while HCG promoters are relatively uniformly less methylated (greater
HELP-tagging signal, panel (a), orange), the LCG promoters have what appears to be a bimodal distribution, with a substantial proportion
showing higher DNA methylation (lower HELP-tagging signal, blue). By taking the group of promoters below the red dashed line (a) and
comparing their expression (panel (b), blue) with the genome-wide pattern (gray), we see that the genes associated with these promoters are
comparably active to those throughout the genome as a whole (density plot of FPKM values). LCG, low-CG dinucleotide observed/expected ratio;
HCG, high-CG dinucleotide observed/expected ratio; RNAPII-Ser5 (P), serine 5-phosphorylated RNA polymerase II; FPKM, fragments per kilobase
per million reads.
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new peaks in the treated and demethylated cells. At these
new peak locations, we found a strong shift towards de-
creased DNA methylation (Figure 7b). RNA-seq is not anideal test for novel promoter use but might be expected to
show an overall expression increase in the situation of the
activation of an additional cryptic promoter. When we
tested the genes where new RNAPII-Ser5 (P) peaks were
Figure 6 (See legend on next page.)
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Figure 6 Limited transcriptional consequences of promoter demethylation by 5-aza-CdR. We show in panel (a) the RefSeq-defined HCG
promoters and in panels (b) and (c) the RNAPII-Ser5 (P)-defined HCG and LCG promoters, respectively. On the left is a plot representing the
k-means clustering of promoter methylation, with a very small proportion of promoters losing DNA methylation in both of the HCG categories
(a, b) but a greater proportion of LCG promoters (c). When we take the genes associated with the k-means subgroups indicated by the colored
percentages and represent their expression changes individually as gray lines and as subgroups depicted by colored lines, again reflecting the
use of k-means clustering, we see very few genes to change expression levels, even though the proportion of promoters changing DNA
methylation in panel (c) was relatively substantial. Percentages in the panels on the right represent proportions of all of the loci tested from the
outset and are directly comparable with the percentages in the panels on the left. For example, while (23.0 + 3.7 + 5.4 =) 32.1% of the 1,338
promoters in panel (c) show loss of DNA methylation, when the expression of the associated genes is studied, only 0.45% of the 1,338 have
induction of expression. LCG, low-CG dinucleotide observed/expected ratio; HCG, high-CG dinucleotide observed/expected ratio; RNAPII-Ser5 (P),
serine 5-phosphorylated RNA polymerase II; FPKM, fragments per kilobase per million reads.
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tion in the proportion of completely silent genes (Figure 7c),
indicating that these intragenic peaks may be involved in
activating previously repressed genes. A total of 76 genes
were found to have new intragenic RNAPII-Ser5 (P) peaks
and induction of expression. This group of genes, when an-
alyzed using Gene Set Enrichment Analysis (GSEA) [24],
were observed to be significantly enriched for targets of
H3K27me3 during differentiation [25] or Polycomb pro-
teins [25,26] (Additional file 1: Table S5).
DNA methylation within the bodies of genes has also
been implicated as a regulator of co-transcriptional spli-
cing events, recruiting MeCP2 for exon recognition [23],
suggesting that demethylation of transcribed gene bodies
may have consequences for splicing and RNA process-
ing. As mentioned earlier, we found the majority of
genes changing expression with 1.0 μM 5-aza-CdR treat-
ment to be loci annotated to have multiple isoforms, so
altered splicing is a possibility at these genes, but these
differentially expressed genes are so limited in propor-
tion that this cannot be said to provide evidence for aFigure 7 Induction of RNAPII-Ser5 (P) by 5-aza-CdR in intragenic loci
show that while the majority of ChIP-seq peaks following 5-aza-CdR exposu
1,902 new peaks found map to intragenic loci (defined as the RefSeq gene
used to define the promoter). The new 1,306 intragenic peaks are found to
and are associated with 519 genes, whose expression before (gray) and aft
decrease in the proportion of completely silenced genes (left peak) is obse
activation of intragenic promoters. 5-aza-CdR, 5-aza-2′-deoxycytidine; RNAP
per kilobase per million reads.h.systematic effect. We tested the alternative possibility
that there may instead be measurable changes in the
processing of the primary transcript. DNA methylation
within a transcribed sequence has been associated with
changing the rate of passage of RNA polymerase
through the body of the gene [27], raising the possibility
that the extensively demethylated gene bodies in our
treated cells would be accompanied by increases in the
amount of primary transcript. The RNA-seq assay we
used is not restricted to the sequencing of processed
mRNAs, allowing us to detect and quantify primary
transcripts present. To quantify the amount of primary
transcript, we calculated the Intronic Retention Score
[28] as a measure of the degree to which the primary
transcript was being sequenced in treated compared
with control cells. Our expectation was that an increased
speed of polymerase in demethylated genes would result
in a skewing of Intronic Retention Scores (IRSs), with an
increase in 5-aza-CdR-treated cells. We show in Figure 8
that there is no such skewing, arguing against the direct
role of DNA methylation in RNA polymerase slowingis associated with activation of silenced genes. In panel (a), we
re already were present in the untreated cells, the majority of the
annotation excluding the ±2 kb around the transcription start site,
decrease DNA methylation (increase HELP-tagging signal, panel (b))
er (blue) 5-aza-CdR treatment is shown using a density plot (c). A
rved in the genes gaining intragenic RNAPII-Ser5 (P), suggesting the
II-Ser5 (P), serine 5-phosphorylated RNA polymerase II; FPKM, fragments
Figure 8 No effect on primary transcript levels was found with 5-aza-CdR exposure. The Intronic Retention Score (IRS) was calculated for
each condition, with the loci changing 2× the standard deviation depicted by green (increased) or red (decreased) as a response to the drug
exposure. No systematic shift to increased IRS with drug exposure was found, a finding that makes it unlikely that the primary RNA transcript is
influenced by gene body demethylation by 5-aza-CdR. 5-aza-CdR, 5-aza-2′-deoxycytidine.
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sine 36 of histone H3 (H3K36me3) as an associated
mark in transcribed gene bodies that is more likely to
mediate polymerase slowing [28].
Characteristics of subset of protein-coding genes with
transcriptional changes
Finally, we turned our focus to the limited subset of
genes with robust expression changes as a response to
5-aza-CdR (Figure 3). To understand the characteristics
of the small subset of genes induced to change expres-
sion with 5-aza-CdR treatment, we performed GSEA on
the genes differentially expressed in the 1.0 μM 5-aza-
CdR-treated cells and found significant enrichment of
several pathways (Additional file 1: Table S6). Three
gene sets predominated. In common with the more lim-
ited group of genes with induction of expression associ-
ated with de novo intragenic promoters, one gene set
reflected Polycomb-targeted loci in human embryonic
stem (ES) cells [25] and genes marked with H3K27me3
in pluripotent cells [26]. A second group of genes isthose that have previously been shown to be induced fol-
lowing in vitro exposure to 5-aza-CdR of human pancre-
atic [29] and multiple myeloma [30] cancer cell lines,
indicating a common set of genes transcriptionally al-
tered by 5-aza-CdR in our non-malignant cells that are
also targeted by the drug in cultured malignant cells.
The third group is a group of genes previously found to
be overexpressed in several epithelial cancers [31-33],
with the Notch pathway a common functional intersec-
tion for these gene groups. We illustrate the network
connectivity and the different pathway representations
of the genes involved in Figure 9.
Discussion
With increasing interest in the use of epigenetically
active drugs to ameliorate human diseases, it is valu-
able to define how these drugs work on a genomic
level, an area of research that has been relatively
under-explored to date, especially in non-malignant
cells. We confirm previous observations that 5-aza-
CdR is extremely powerful in demethylation of the
Figure 9 The genes affected by 5-aza-CdR are comparable in multiple cell types and represent targets of Polycomb in ES cells. A
depiction of the interactions of the genes changing expression in response to 1.0 μM 5-aza-CdR (large circles of any color) with genes induced to
express in myeloma cells (blue) and a highly overlapping set of genes induced to express by 5-aza-CdR in pancreatic cancer cells and genes
up-regulated in breast cancer (orange), as well as genes that represent targets of Polycomb-mediated repression in ES cells (yellow). Genes
involved in multiple gene sets combine those colors. These results indicate that our results in HEK 293 T cells may represent genomic responses
in human cells more generally and suggests a mechanism based on reversing Polycomb effects that may mediate the drug’s therapeutic benefits
in MDS. 5-aza-CdR, 5-aza-2′-deoxycytidine.
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methylation is targeting gene-rich, transcriptionally active
euchromatin. We also observe a long-lasting imprint in
cells no longer exposed to the drug, which has previously
been found to occur at the majority of loci in the genome
of HCT116 cells treated with 0.3 μM of 5-aza-CdR, with
the demethylation imprint still present 42 days after drugexposure [34]. This is of interest as a potential model of ac-
quired resistance to an epigenetically active drug - if a locus
is already demethylated, it has become refractory to further
demethylation. In spite of the disproportionate targeting of
euchromatin, our data are consistent with prior reports in-
dicating that transcriptional effects are limited to a small
subset of protein-coding genes, with a similar effect on
Ramos et al. Epigenetics & Chromatin  (2015) 8:11 Page 12 of 17lncRNAs. This is despite the measurable demethylation of
RefSeq and RNAPII-Ser5 (P)-defined promoters and the
emergence of new promoters defined by loci acquiring
RNAPII-Ser5 (P). A clue to the mechanism of transcrip-
tional activation of 5-aza-CdR comes from the discovery
that the intragenic acquisition of RNAPII-Ser5 (P) appears
to be associated with the activation of previously silenced
genes, possibly supporting a model of limited cryptic pro-
moter activation [35]. The fact that we do not observe sub-
stantial gene activation is unexpected, as the common
belief is that DNMT1 inhibitors should have this property.
It may be significant that many previous studies have used
malignant cells whereas we are using transformed HEK
293 Tcells, which are not derived from a primary cancer.
In defining promoter categories, we made the unex-
pected discovery that the previous definition of LCG
promoters [21] appears to over-represent those used
in vivo, based on a comparison with those defined by
ChIP-seq data for RNAPII-Ser5 (P). As the majority of
the genome is depleted in CG dinucleotides, a random
sampling of the genome included in this kind of analysis
would relatively inflate the LCG proportion, suggesting
that RefSeq-defined promoters in the LCG category
should be viewed as annotations of questionable reliabil-
ity. Another finding of interest about promoters was that
RNAPII-Ser5 (P) can be located at methylated DNA and
that the associated genes show patterns of expression
that appear comparable to those in the remainder of the
genome. This is a puzzling observation. One concern
with any study that finds co-localization of genomic
regulatory events is that co-localization does not neces-
sarily imply the presence of the two events on the same
alleles in the population of cells being tested. Scrutiniz-
ing the HELP-tagging data of Figure 5, it is clear that a
substantial proportion of the readings are at loci of inter-
mediate methylation, which supports a model of mixed
allelic populations, allowing the RNAPII-Ser5 (P) to be
present on a subset of alleles that are unmethylated. Fur-
ther work will be necessary to resolve this unexpected
finding.
The effect of pharmacological demethylation on pro-
moters and transcription was limited and frequently
uncoupled - promoters with methylation changes did
not necessarily change the expression status of the asso-
ciated gene. It has already been shown that some pro-
moters can remain occupied by nucleosomes following
pharmacological demethylation [13], and it is also pos-
sible that the lack of cognate transcription factors may
be a reason why the acquisition of permissiveness, in
terms of DNA methylation, is not accompanied by the
induction of gene expression. The results of this study
serve to emphasize that transcriptional regulation is a
complex system that cannot readily be interpreted in
terms of a single component like DNA methylation.The relationship of DNA methylation with transcription
in gene bodies has been recognized for some time to be dif-
ferent from that at promoters, referred to as ‘the methyla-
tion paradox’ [36], possibly serving a role to repress cryptic
intragenic transcription [23], although this role has been
questioned [37]. DNA methylation is also linked to co-
transcriptional splicing regulation [35] and to modulation
of the rate of RNA polymerase passage through the tran-
scribed region [27]. Together, these prior observations indi-
cate that we should expect changes in qualitative aspects of
gene expression when DNA demethylation is occurring and
disproportionately targeting transcribed regions of the gen-
ome. While there is some evidence for de novo establish-
ment of RNAPII-Ser5 (P) promoters within gene bodies
associated with 5-aza-CdR exposure, with limited transcrip-
tional consequences, little evidence exists for altered pri-
mary transcript processing. While there is some evidence
for activation of a small number of cryptic intragenic pro-
moters, the effect is so small that it argues against a major
reason for DNA methylation being to suppress transcrip-
tional noise, as previously proposed [15].
A goal of the project was to understand why 5-aza-
CdR targeted certain loci preferentially. As should be
predicted, loci that are heavily methylated before treat-
ment are more likely to become unmethylated as a re-
sponse to the drug, which leads to our being able to
define euchromatin as the major target compartment, as
well as specific promoter subtypes that are more likely
to be methylated. Unexpectedly, we found evidence that
the genes that we found to change expression in HEK
293 T cells are significantly similar to those changing ex-
pression in malignant multiple myeloma and pancreatic
cells exposed to 5-aza-CdR in vitro [29,30]. This indi-
cates that there is a common set of human genes that
respond to 5-aza-CdR, suggesting that the data we gen-
erated in HEK 293 T cells may be more broadly applic-
able to other human cell types. The genes induced to
express show a strong enrichment for those implicated
by Ben-Porath and colleagues [25] to represent the genes
at which Polycomb-mediated silencing in ES cells is tar-
geted. A model for cancer formation involving Polycomb
proposes that silencing to create a pluripotent stem-cell-
like epigenetic pattern is part of the induction of a self-
renewal program that favors neoplasia [38]. The prefer-
ential demethylation and gene activation by 5-aza-CdR
at targets of Polycomb-mediated silencing represents a
tenable model for the drug’s therapeutic effects in MDS,
consistent with the emerging body of evidence that
MDS has a stem cell origin [39]. Set against this poten-
tial therapeutic benefit is the concern that 5-aza-CdR
targets euchromatin, where associated chromosomal
breakage would be directed towards the most gene- and
transcriptionally enriched genomic compartment. This
issue raises concerns about the risk:benefit ratio with
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justifiable in cancer treatment, as currently permitted,
but may be more difficult to justify in less life-
threatening disorders involving epigenetic changes.
Conclusions
The use of powerful genome-wide assays to study the ef-
fects of pharmacological DNMT1 inhibition has confirmed
several prior findings, including limited transcriptional ef-
fects despite profound global demethylation. New findings
include the observation that demethylation can persist as
an epigenetic imprint following drug withdrawal and cell
recovery. In addition to the limited effects of demethylation
by 5-aza-CdR on protein-coding genes, we see similar lim-
ited effects on lncRNAs and primary RNA transcript pro-
cessing. This is an unexpected finding given the multiple
prior reports of transcriptional activation following
DNMT1 inhibitor treatment, but we note that the HEK
293 T cells that we study are not derived from malignant
cells as are typically studied, potentially helping to explain
this difference. Our use of ChIP-seq to define promoters re-
veals some potential limitations to current genomic annota-
tions of transcriptional start sites and some new insights
about the CG dinucleotide content and DNA methylation
patterns at these in vivo promoters. We find evidence that
the limited effects on transcription of protein-coding genes
in HEK 293 Tcells may involve activation of intragenic pro-
moters, while similarities observed in the genes induced to
express in our study with those in other human cell types
treated in the same manner suggest that our results may
apply to other cell types. We find support for 5-aza-CdR
having effects that reverse Polycomb-mediated silencing,
suggesting a mechanism for its therapeutic effect in MDS.
While HEK 293 T cells are not derived from malignant
cells, neither are they primary, untransformed cells, so
we have to be cautious about interpreting how our
findings translate to other cell types, but the preferen-
tial targeting of euchromatin for demethylation raises
the concern that 5-aza-CdR may also have clastogenic
properties, requiring caution in the use of this drug
clinically for non-cancer conditions involving epigenetic
dysregulation.
Methods
Cell culture and 5-aza-CdR treatment
We chose to work with the widely available and well-
characterized HEK 293 T transformed, non-malignant
cells, in order to avoid any bias that passage number
could introduce in the analysis. HEK 293 T cells were
grown in DMEM supplemented with 10% fetal bovine
serum and 2 mM penicillin-streptomycin at 37°C in 5%
CO2. 5-aza-CdR was dissolved in water to a final con-
centration of 10 mg/mL and stored in aliquots at −20°C.
The 5-aza-CdR treatment was optimized to establish aworking concentration, using a range from 0.25 to
2.0 μM. The cells were exposed to 5-aza-CdR for 3 days
to allow the drug to be incorporated into DNA. Tissue
culture medium was changed every day for both control
and treated cells, to maintain the drug stability during
treatment.
HEK 293 T cells were grown in triplicates for each
condition, including a control group with no drug ex-
posure. To allow recovery of the cells after the 3-day
treatment, we maintained the treated cells in culture
with fresh media lacking drug. Cells were passaged only
when reaching 80% to 90% confluence, for a total
period of 1 month. Cells were washed before trypsiniz-
ing to ensure that only adherent, viable cells were pas-
saged. DNA, RNA, protein, and cross-linked chromatin
were extracted from the same cell batch for each
condition.
Cell metabolism assay
Cells were seeded in 96-well plates using the same ex-
perimental conditions as for the 5-aza-CdR experi-
ments. At the end of each time point, the WST-1
assay (Clontech) was performed following the manu-
facturer’s recommendations. Absorbance reads were
registered after 40 min of incubation for 16 replicates
at each time point and normalized by the number of
cells present to quantify the net metabolic activity of
the cells in culture. A total of 12 replicates were
performed.
Sample preparation
DNA, RNA, and cross-linked chromatin were extracted
from the same cell batch for each condition. For DNA
extraction, cells were re-suspended in lysis buffer
(10 mM Tris EDTA (TE), 150 mM ethylenediaminetet-
raacetic acid (EDTA), and 1% sodium dodecyl sulfate
(SDS)) supplemented with 10 mg/mL of RNase A and
20 mg/mL of Proteinase K and incubated at 50°C over-
night. The lysed cells were phenol-chloroform extracted,
and the resultant DNA was dialyzed in 0.2× SSC buffer
(300 mM NaCl and 3 mM Na3C6H5O7, ph 7.0) for 24 h.
The DNA sample was concentrated in the dialysis bags
using polyethylene glycol, following which the quality
and concentration of the DNA were measured by Nano-
Drop spectrophotometry. RNA was extracted using TRI-
zol (Invitrogen) using the manufacturer’s protocol. The
quality and integrity of the RNA were measured using
NanoDrop spectrophotometry and Bioanalyzer (Agilent).
For chromatin, cells were processed using the Myers
Lab ChIP-seq protocol [40]. The untreated and 1.0 μM
acutely treated cells were cross-linked in culture media
with 1% formaldehyde for 10 min, quenching with
0.125 M Glycine. The cells were then washed with cold
PBS, collected by centrifugation at 2,000 rpm for 5 min
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PIPES (pH 8.0), 85 mM KCl, 0.5% NP-40, supplemented
with fresh protease inhibitor cocktail (Roche)). Following
collection, the crude nuclear preparation was re-
suspended in 300 μL of cold radioimmunoprecipitation
assay (RIPA) buffer (1× PBS, 1% NP-40, 0.5% sodium
deoxycholate, 0.1 SDS, supplemented with fresh protease
inhibitor cocktail (Roche)) and processed in a Bioruptor
at the high setting. HEK 293 T cells were sonicated for a
total of 15 min, in cycles of 30 s on/30 s off. The soni-
cated mixture was spun at 16,000 × g for 15 min at 4°C,
and the chromatin was collected from the supernatant.
The sample volume was brought to 1 mL with RIPA buf-
fer, and 100 μL was saved as an input control.
Luminometric methylation assay (LUMA)
To quantify global DNA methylation changes, LUMA
analysis was performed [16]. For each time point, each
of the DNA samples was digested in triplicate with 20 U
EcoRI and either MspI or HpaII at 37°C overnight, puri-
fied and submitted to our institutional Genomics Core
Facility for pyrosequencing. The percentage of methyla-
tion was calculated by the ratio of the incorporated (C +
G) nucleotides after the HpaII digestion compared with
the MspI digestion and normalized to the values ob-
tained by EcoRI digestion ((A + C)/2).
HELP-tagging assay
As previously described [41], 1 μg of DNA was used to
generate HELP-tagging libraries. The indexed adapters
used are listed in Additional file 1: Table S7. Genomic
DNA was digested with either MspI or HpaII at 37°C
overnight, purified and ligated to the first pre-annealed
TruSeq-indexed Illumina adapters containing the T7
promoter sequence, as well as the EcoP15I recognition
site (AE adapters [41]). After ligation, the DNA samples
were digested with EcoP15I at 37°C overnight, end-filled,
3′ terminal A extended and ligated to the second pre-
annealed Illumina adapter (AS adapter). Samples were
then in vitro transcribed using the MEGAshort kit
(Ambion), followed by retrotranscription (SuperScript
III kit, Invitrogen) before amplification. Libraries were
multiplexed for 50 bp single-end sequencing on the Illu-
mina HiSeq 2500 platform at the institutional Epige-
nomics Shared Facility.
Directional RNA-seq assay
DNase-treated, rRNA-depleted (Ribozero, Epicentre) RNA
was used as a template for SuperScript III first-strand
cDNA synthesis (Invitrogen), using oligo-dT as well as
random hexamers. Actinomycin D was added to the reac-
tion to prevent any possible amplification from contamin-
ating genomic DNA. During second-strand synthesis, a
dU/VTP mix was used to create directional libraries.Before library preparation, cDNA samples were Covaris-
fragmented to 300-bp fragments. The samples were then
end-filled, 3′ terminal A extended and ligated to pre-
annealed TruSeq-indexed Illumina adapters. Uracil-DNA-
glycosylase (UDG) treatment preceded the PCR reaction
to amplify exclusively the originally oriented transcripts.
Libraries were amplified using P5 and P7 Illumina primers
and gel-extracted for size selection and primer-dimer re-
moval. Before sequencing, libraries were tested using the
BioAnalyzer to assure library quality, in terms of size and
primer-dimer depletion. Indexed libraries were multi-
plexed for 100-bp single-end sequencing on the Illumina
HiSeq 2500 platform at the institutional Epigenomics
Shared Facility. The indexed adapters used are listed in
Additional file 1: Table S8. Given the concordance of ex-
tremely limited effects on transcription for different time
points and drug dosages, and following recommendations
of ENCODE for RNA-seq experiments [19], we allowed
the four treatment conditions to act as biological repli-
cates, increasing confidence in our findings of minimal
transcriptional effects of 5-aza-CdR.
ChIP-seq assay
Chromatin immunoprecipitation was performed using 3 ×
106 cells using the Myers Lab ChIP-seq protocol [40]. HEK
293 T cells were crosslinked in culture media with 1% for-
maldehyde for 10 min, quenching with 0.125 M Glycine.
The cells were then washed with cold PBS, collected by
centrifugation at 2,000 rpm for 5 min at 4°C, and resus-
pended in cold Farnham lysis buffer (5 mM PIPES (pH 8.0),
85 mM KCl, 0.5% NP-40, supplemented with fresh protease
inhibitor cocktail (Roche)). Following collection, the crude
nuclear preparation was resuspended in 300 μL of cold
RIPA buffer (1× PBS, 1% NP-40, 0.5% sodium deoxycholate,
0.1 SDS, supplemented with fresh protease inhibitor cock-
tail (Roche)) and processed in a Bioruptor at the high set-
ting. HEK 293 T cells were sonicated for a total of 15 min,
in cycles of 30 s on/30 s off. The sonicated mixture was
spun at 16,000 × g for 15 min at 4°C, and the chromatin
was collected from the supernatant. The sample volume
was brought to 1 mL with RIPA buffer, and 100 μL was
saved as an input control. Magnetic beads (Invitrogen) were
washed three times with 5 mg/mL BSA in PBS and supple-
mented with freshly added protease inhibitors. RNAPII-
Ser5 (P) antibody (5 μg, Active Motif catalog number
#61085) was added to the bead slurry, incubating the mix-
ture overnight at 4°C. The antibody-coupled beads were
washed three times with PBS/BSA, added to the chromatin
sample, and incubated in a rotor at 4°C overnight.
After immunoprecipitation, beads were collected by
magnetic separation and washed five times with cold LiCl
Wash buffer (100 mM Tris–HCl pH 7.5, 500 mM LiCl,
1% NP-40, 1% sodium deoxycholate). After a final wash
with cold 1× TE buffer, the beads were resuspended in
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containing proteinase K and 0.2 M NaCl), and both
the immunoprecipitated and input samples were de-
crosslinked at 65°C overnight. ChIP products were puri-
fied with the DNA Clean and Concentrator kit (Zymo)
and eluted in 60 μL of elution buffer. The efficiency of the
ChIP was tested by enrichment quantification of immuno-
precipitated/input DNA ratios at candidate positive loci
compared with those at negative regions, using real-time
quantitative PCR (RT-qPCR). The primers used are pre-
sented in Additional file 1: Table S9. For library prepar-
ation, the samples were end-filled, 3′ terminal A extended
and ligated to pre-annealed TruSeq-indexed Illumina
adapters. The indexed adapters used are listed in Additional
file 1: Table S10. Libraries were amplified using P5
(5′-AATGATACGGCGACCACCGA-3′) and P7 (5′-CAA
GCAGAAGACGGCATACGAGAT-3′) Illumina primers
and gel extracted for size selection and primer-dimer re-
moval. Before sequencing, the quality of the libraries was
checked using the Agilent BioAnalyzer to confirm the cor-
rect size (250 to 500 bp) and primer-dimer depletion. Li-
braries were multiplexed and single-end sequenced on the
Illumina HiSeq 2500 with 100-bp read length at the insti-
tutional Epigenomic Shared Facility.
HELP-tagging data analysis
Sequencing reads were aligned by the WASP pipeline
[42] version 3.1.4 (rev. 6598), using the CASAVA aligner
from Illumina (ELAND 1.7.0). Transformation of raw se-
quence reads to the angle calculation previously de-
scribed [41] was performed using an MspI reference
from HEK 293 T cells and scaled to create a 0 to 100
range. Data analysis was performed using a bespoke
pipeline in the R environment (version 2.15.0). A median
of 4.5 million reads was obtained for each sample, with
98% of them passing filter and 76% aligning to the refer-
ence genome.
RNA-seq data analysis
For RNA-seq analysis, sequencing reads were aligned by
the WASP pipeline [42] version 3.1.3 (rev. 6589) using
gsnap (2012-07-20) [43]. Cufflinks tools [18] version 2.1.1
were then used to assemble aligned RNA-seq reads into
transcripts, estimate their abundances, and test for differen-
tial expression and regulation [18]. For each sample, 15.5
million reads were obtained on average, 89% of them pass-
ing filter and 93% aligning to the reference genome. Cuf-
flinks was used to calculate the score of FPKM for each
transcript. To generate reference genomes, GTF files were
obtained from the UCSC Genome Browser. We used the
Cuffdiff package [18] to compare FPKM values and obtain a
list of differentially expressed genes. k-Means clustering was
used to group RefSeq gene expression levels. For the esti-
mation of intronic retention, the IRS was calculatedfollowing the previously reported approach [28]. The for-
mula employed is presented below:
IRS ¼ 2
Σ intronic coverageintronic length
Σ exonic coverageexonic length þ Σ intronic coverageintronic length
By calculating the ratio between control and tested
samples, and then considering the genes with a ratio
greater than 2× the standard deviation, we obtained a list
of the candidate genes with the most extreme intronic
retention.ChIP-seq data analysis
ChIP-seq reads were aligned by the WASP Pipeline [42]
version 3.1.5, using MACS [44] version 1.4.2 as the peak
finder and bowtie [45] version 0.12.7 as the aligner. A
median of 19 million reads was obtained for each sample,
with 89% of them passing filter and 77% aligning to the
reference genome. Data analysis was performed using a
bespoke pipeline within the R environment (version
2.15.0).Self-organizing map analysis
To examine the relationships between five different genomic
variables, we used an artificial neural-learning-based ap-
proach, the self-organizing map (SOM) [46]. We used
100-kb sliding windows with a step size of 50 kb as we have
previously described [14]. To build the SOM, we used infor-
mation from HELP-tagging data for control samples and
the acute values for the 1.0 μM 5-aza-CdR-treated cells, the
mean of gene expression levels of all RefSeq genes within the
window, and the cumulative number of HpaII sites per win-
dow. All vectors were tagged by 5-aza-CdR response and
whether they belonged to one of the five quartiles of DNA
methylation and gene expression levels. After training, all
data were re-introduced to the grid a final time and selected
annotations revealed as a dual color intensity graph in order
to examine the distribution of features. Overall clustering
patterns in the data were also examined using a U-matrix
representation of the grid, which represents a similarity
graph where a linear grayscale is used to indicate how similar
a node vector is to its immediate neighbors in vector space.Promoter categorization
Replicating a previously published approach [21], we cat-
egorized promoters based on CG dinucleotide content.
A cutoff of 0.366 was established at the local minimum
of the bimodal distribution for the observed/expected
CG ratio of all RefSeq promoters (±1.5 kb flanking the
TSS), while the cutoff for the RNAPII-Ser5 (P) pro-
moters was 0.401.
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